Literature DB >> 19135223

Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.

Antu K Dey1, Kathryn B David, Min Lu, John P Moore.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) entry into host cells is mediated by the trimeric envelope glycoprotein complex (Env). Accordingly, the Env proteins are the targets for neutralizing antibodies (NAbs) and are the focus of vaccines intended to induce NAbs. Because the Env complex is labile, soluble recombinant Env (gp140) trimers require engineering to stabilize them sufficiently for use as immunogens. Trimeric forms of gp140 trimers can be created that are either cleavage-competent or cleavage-defective at the junction between the gp120 and gp41 subunits. As functional trimers are cleaved at this site, the question arises as to whether cleavage affects the antigenic structure of the Env complex in a way that is relevant to vaccine design. Here, we present a comparative analysis of the antigenicity profiles of cleaved and uncleaved gp140 trimers derived from the KNH1144 (subtype A) virus that are otherwise closely sequence-matched. While cleavage did not affect the exposure of NAb epitopes on the gp140 trimers, non-neutralizing antibodies to gp41 epitopes bound much more strongly to uncleaved trimers. Hence cleavage does alter the structure of the HIV-1 Env complex.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135223      PMCID: PMC3795524          DOI: 10.1016/j.virol.2008.12.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  PE2 cleavage mutants of Sindbis virus: correlation between viral infectivity and pH-dependent membrane fusion activation of the spike heterodimer.

Authors:  J M Smit; W B Klimstra; K D Ryman; R Bittman; R E Johnston; J Wilschut
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes.

Authors:  Otto O Yang; Phuong Thi Nguyen; Spyros A Kalams; Tanya Dorfman; Heinrich G Göttlinger; Sheila Stewart; Irvin S Y Chen; Steven Threlkeld; Bruce D Walker
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl L Wiley; Linnea Schiffner; Bruce Travis; Shawn Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base.

Authors:  Lisa Cavacini; Mark Duval; Leslie Song; Rebecca Sangster; Shi-hua Xiang; Joseph Sodroski; Marshall Posner
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

8.  A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.

Authors:  Mark Duval; Marshall R Posner; Lisa A Cavacini
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Authors:  Norbert Schülke; Mika S Vesanen; Rogier W Sanders; Ping Zhu; Min Lu; Deborah J Anselma; Anthony R Villa; Paul W H I Parren; James M Binley; Kenneth H Roux; Paul J Maddon; John P Moore; William C Olson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  25 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

3.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

4.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

5.  Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding.

Authors:  Carlos G Moscoso; Yide Sun; Selina Poon; Li Xing; Elaine Kan; Loïc Martin; Dominik Green; Frank Lin; Anders G Vahlne; Susan Barnett; Indresh Srivastava; R Holland Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

6.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 7.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.

Authors:  Li Liu; Raffaello Cimbro; Paolo Lusso; Edward A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-29       Impact factor: 11.205

9.  Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.

Authors:  Aaron Wallace; Leonidas Stamatatos
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.

Authors:  Miklos Guttman; Kelly K Lee
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.